2nd International Conference on
Tumor & Cancer Immunology and Immunotherapy
July 17-18, 2017 Chicago, USA

Theme: “Emerging Technologies and treatment in Tumor & Cancer Immunotherapy from vaccines to antibodies and cell therapies”

**For Available Speaker Slots**
tumor@immunologyconferences.org

Conference Secretariat
Conference Series LLC 2360 Corporate Circle, Suite 400 Henderson, NV 89074-7722, USA
Email: tumor@immunologyconferences.org, cancer@immunologyconferences.org
### SCIENTIFIC PROGRAM

#### Day 1, July 17, 2017

**Keynote Forum**

**Title:** Chimeric antigen receptor modified T cell redirected to EGFR in patients with metastatic and advanced pancreatic adenocarcinoma and biliary tract cancers  
Weidong Han, PLA General Hospital, China

**Title:** Absence of Grail promotes CD8+ T cell anti-tumor activity  
Roza Nurieva, Anderson Cancer Center, TX, USA

**Title:** Quantitative and Reproducible Cell-Based Bioassays to Advance Immunotherapy Programs  
Gopal Krishnan, Global Product Manager- Bioassays, Promega Corporation, USA

**Special Session**

**Title:** A novel oncolytic HSV-1 vector for cancer immunotherapy  
William Jia, University of British Columbia, Canada

**Workshop**

**Title:** Immunotherapy for thoracic cancers: challenges and success  
Alessandra Curioni Fontecedro, University Hospital of Zurich, Switzerland

**Sessions**

- Immunotherapy - Tumors  
- Cancer Immunology & Immunotherapy  
- Cancer Research  
- Tumor Immunotherapy Research  
- Tumor Markers and Drug Targetting

**Title:** Diagnostic and prognostic markers in Non-Hodgkin's Lymphoma  
Manal Mohamed Saber, Minia University, Egypt

**Title:** Oncologic impact of postoperative delta-neutrophil index in pancreatic cancer  
Sung Hwan Lee, Yonsei University College of Medicine, Seoul, Korea

**Title:** The tumor microenvironment is correlated with clinicopathological traits and indicates the adjuvant chemotherapeutic efficacy of gemcitabine in pancreatic cancer after curative Whipple procedure  
Qiaofei Liu, Chinese Academy of Medical Sciences, China

**Title:** Comparative analysis of immune molecules in esophageal squamous cell carcinoma and adenocarcinoma  
Guohui Qin, Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Henan, China.

**Title:** Cancer stem cell vaccine significantly reduced local tumor relapse and prolonged animal survival in the adjuvant setting  
Qiao Li, University of Michigan Comprehensive Cancer Center, USA

#### Panel Discussion

### Day 2, July 18, 2017

**Keynote Forum**

**Title:** A Tetramer HLA-A Platform amenable to exchange peptides can be used to measure and predict the biological activity of a cancer vaccine  
Marc Delcommenne, Rush University Medical Center, Chicago, USA

**Sessions**

- Immunotherapy - Tumors  
- Cancer Immunology & Immunotherapy  
- Cancer Research  
- Tumor Immunotherapy Research  
- Tumor Markers and Drug Targetting

**Title:** The tumor microenvironment is correlated with clinicopathological traits and indicates the adjuvant chemotherapeutic efficacy of gemcitabine in pancreatic cancer after curative Whipple procedure  
Qiaofei Liu, Chinese Academy of Medical Sciences, China

**Title:** A novel oncolytic HSV-1 vector for cancer immunotherapy  
William Jia, University of British Columbia, Canada

**Title:** Immunotherapy for thoracic cancers: challenges and success  
Alessandra Curioni Fontecedro, University Hospital of Zurich, Switzerland

**Title:** Comparative analysis of immune molecules in esophageal squamous cell carcinoma and adenocarcinoma  
Guohui Qin, Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Henan, China.

**Title:** Cancer stem cell vaccine significantly reduced local tumor relapse and prolonged animal survival in the adjuvant setting  
Qiao Li, University of Michigan Comprehensive Cancer Center, USA
<table>
<thead>
<tr>
<th>Title</th>
<th>Author(s)</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emap II-Induced Immune Suppression In Colorectal Cancer</td>
<td>Manal Mohamed Saber</td>
<td>Minia University, Egypt</td>
</tr>
<tr>
<td>Phase I clinical trials for the PD-1/MUC1 CAR-pNK92 immunotherapy</td>
<td>Leiming Xia</td>
<td>University of Michigan Comprehensive Cancer Center, USA</td>
</tr>
<tr>
<td>Adoptively transferred B cells directly kill tumor cells via the CXCR4/CXCL12 and perforin pathways</td>
<td>Lu Wen</td>
<td>University of Michigan Comprehensive Cancer Center, USA</td>
</tr>
<tr>
<td>Bacteria: friends or foes? Anticancer immune strategy by attenuated mutant strain of Salmonella Typhimurium (STMZNUABC)</td>
<td>Barbara Chirullo</td>
<td>Istituto Superiore di Sanità, Italy</td>
</tr>
<tr>
<td>Projected role of modified-albumin in cancer</td>
<td>Zarina Arif</td>
<td>Aligarh Muslim University, U.P, India</td>
</tr>
<tr>
<td>Mitochondrial DNA Copy Number Variation as a Potential Predictor of Renal Cell Carcinoma</td>
<td>Eman Tayae Elsayed</td>
<td>Alexandria University, Egypt</td>
</tr>
<tr>
<td>T cell suppression is associated with circulating and tumor infiltrating CD33+11b+HLA-DR- myeloid suppressor cells in gastric cancer: A possible relation to MicroRNA-494 and TGF-β tumor expression</td>
<td>Mai Moaaz</td>
<td>Alexandria University, Egypt</td>
</tr>
<tr>
<td>The Interplay of Interleukin-17A (IL-17A) and Breast cancer tumor microenvironment as a novel approach to increase tumor immunogenicity</td>
<td>Mai Moaaz</td>
<td>Alexandria University, Egypt</td>
</tr>
<tr>
<td>Inhibition of Eva1 degrade the formation and development of glioblastomas</td>
<td>Naoki Ohtsu</td>
<td>Hokkaido University, Japan</td>
</tr>
<tr>
<td>Clinical study of Hemagglutinating virus of Japan envelope against chemotherapy resistant pleural mesothelioma</td>
<td>Chunmna Lee</td>
<td>Osaka University, Japan</td>
</tr>
<tr>
<td>Is elevated troponin T reliable enough to be the only screen-out factor in pre-treated lymphoma patients?</td>
<td>Nickolai Usachev</td>
<td>PSI Company, Ltd., Russia</td>
</tr>
<tr>
<td>T Helper Subset Cell Activation and Activated T Cell Autonomous Death (ACAD) Dedicated by Peptidylarginine Deiminase 2 through an ER Stress and Autophagy Mechanism</td>
<td>Guang-Yaw Liu</td>
<td>Chung Shan Medical University Hospital, Taichung, Taiwan</td>
</tr>
<tr>
<td>A Novel Mechanism Regulating Polyamine Homeostasis through an Antizyme Citrullination Pathway</td>
<td>Hui-Chih Hung</td>
<td>National Chung Hsing University, Taichung, Taiwan</td>
</tr>
</tbody>
</table>
TOURIST DESTINATIONS IN CHICAGO

- Art Institute of Chicago
- Chicago Shakespeare Theater
- Cloud Gate
- Millennium Park
- Museum of Science and Industry
- Navy Pier
- Rookery Building
- Shedd Aquarium
- Willis Tower
- Wrigley Field Chicago Club
Conference Venue

Doubletree by Hilton Chicago North Shore Conference Center
9599 Skokie Boulevard, Skokie, Illinois, 60077-1314, USA
Scientific Program

International Conference on

Tumor & Cancer Immunology and Immunotherapy

July 28-30, 2016   Melbourne, Australia

Hosting Organizations: Conference Series LLC
2360 Corporate Circle., Suite 400 Henderson, NV 89074-7722, USA
Ph: ++1-888-843-8169, Fax: +1-650-618-1417, Toll free: +1-800-216-6499

Conference Series Ltd
Heathrow Stockley Park Lakeside House, 1 Furzeground Way, Heathrow, UB11 1BD, UK, Tel: +1-800-216-6499
Email: tumorimmunology@immunologyconferences.com, cancerimmunology@immunologyconferences.com
**Day 1    July 28, 2016**

**Registrations**

**Melrose**

**Opening Ceremony**

**Keynote Forum**

- **Introduction**
  - **Title:** Immunomodulatory and anti-tumor activities of conjugated linolenic acids
  - **KN Leung,** The Chinese University of Hong Kong, China

- **Title:** Beyond immune checkpoint: Targeting soluble NKG2D ligands for cancer immunotherapy
  - **Jennifer Wu,** University of South Carolina, USA

**Networking & Refreshments Break: @ Tullamarine**

- **Title:** Antibody based immunotherapy targeting pancreatic cancer stem cells
  - **Liang Xu,** University of Kansas Cancer Center, USA

**Workshop**

- **Title:** Phase I/IIa trial of chimeric antigen receptor modified T cells against CD133 in patients with sorafenib refractory hepatocellular carcinoma (HCC) and other solid tumors
  - **Weidong Han,** PLA General Hospital, China

**Group Photo**

**Lunch Break @ Vargas Restaurant**

**Special Session**

- **Title:** Drug development for EGFR-TKI resistance in non-small cell lung cancer cells: Novel dual inhibitor of EGFR and cMET
  - **Hsu-Shan Huang,** Taipei Medical University, Taiwan

**Sessions:**
- Immunotherapy - Tumors
- Cancer Immunology & Immunotherapy
- Cancer Research
- Tumor Immunotherapy Research
- Tumor Markers and Drug Targeting

**Session Chair:** **Liang Xu,** University of Kansas Cancer Center, USA

**Session Introduction**

- **Title:** CSF-470 vaccine plus BCG plus rhGM-CSF show superiority vs IFN-α2b in high risk Cutaneous Melanoma patients stages IIB, IIC and III. Interim results of the phase II part of phase II/III CASVAC0401 study
  - **María Marcela Barrio,** Centro de Investigaciones Oncologica Foundation Cancer – FUCA, Argentina

- **Title:** Immune system, emotional problems and stress in kids and teens with cancer of Cochabamba, Bolivia
  - **Maria del Rosario Dávalos Gamboa,** University of San Simón, Bolivia

**Networking & Refreshments @ Tullamarine**

- **Title:** Oncolytic HSV-1 with enhancement of both oncolysis and safety
  - **William Jia,** University of British Columbia, Canada

- **Title:** Immunoglobulin G4 (IgG4)-positive plasma cell infiltration is associated with the clinicopathologic traits and prognosis of pancreatic cancer after curative resection
  - **Qiaofei Liu,** Chinese Academy of Medical Sciences, China

**Panel Discussion**
Day 2    July 29, 2016

Melrose

Keynote Forum

Title: Intra-tumoral injection of dendritic cells induces specific anti-tumor killer T-cell activity
Kenichiro Hasumi, Hasumi International Research Foundation, Japan

Title: Imaging in cancer immunology: Phenotyping of multiple immune cell subsets \textit{in situ} in FFPE tissue sections
James Mansfield, Director of Tissue application PerkinElmer, USA

Networking & Refreshments Break: @ Tullamarine

Sessions:
Immune System - Tumors
Immune Checkpoint Inhibitors
Combining Cancer Immunotherapies
Cancer Micro and Immuno Environment
Tumor Biology

Session Chair: Kenichiro Hasumi, Hasumi International Research Foundation, Japan

Title: Immune profile and survival outcomes in stage 2 colon cancer
Ben Tran, Eliza Hall Institute of Medical Research, Australia

Title: The significance of lymph node macrophages in the induction of anti-cancer immune response
Yoshihiro Komohara, Kumamoto University, Japan

Title: Autoimmune disorders and Lymphoma
Nalini Kant Pati, Australian National University, Australia

Lunch Break @ Vargas Restaurant

Title: The role of Immunotherapy for stem cell cancer
Purwati Armand, Stem Cell Research and Development Centre Universitas Airlangga, Indonesia

Title: Tumour associated Tie2+ macrophages: Novel targets and effectors of anti-breast cancer therapies
Roberta Mazzieri, The University of Queensland Diamantina Institute, Australia

Panel Discussion

Poster Presentations @ Tullamarine

Title: Neutrophil-to-lymphocyte ratio (NLR) as a prognostic factor for long-term interleukin-2 (IL-2) use in metastatic renal cell carcinoma
Takehiko Okamura, Anjo Kosei Hospital, Japan

Title: Molecular tumor markers: Diagnosis and Therapy
Hussein A Kaoud, Cairo University, Egypt

Title: Determination of a cut-off point for Prostatic Specific Antigen (PSA) to avoid unjustified biopsy among asymptomatic Egyptians
Ibrahim, Afa, Alexandria University, Egypt

Title: Novel drug delivery platform for the topical treatment of cancer
Yaman Tayyar, Griffith University, Australia

Title: \textit{In vitro} and \textit{in vivo} evaluation of novel folate-targeted polymer-lipid hybrid nanoparticles for paclitaxel delivery
Dunwan Zhu, Chinese Academy of Medical Sciences, China

Networking & Refreshments Break: @ Tullamarine

Day 3    July 30, 2016

Melrose

Sessions:
Immunotherapy Monitoring
Cancer Biomarkers
Engineered T-Cell Therapy
Novel Approaches

Session Chair: KN Leung, The Chinese University of Hong Kong, China

Session Introduction
Title: Beyond CTLA-4 and PD-1: Orphan nuclear receptor NR2F6 as T cell signaling switch and emerging target in cancer immunotherapy
Victoria Klepsch, Medical University Innsbruck, Austria

Title: Bispecific antibodies in breast cancer immunotherapy, the path forward?
Joanie DEL BANO, Aix-Marseille University, France

Title: Role of Mast Cells in oral squamous cell carcinoma
Shimae Nafarzadeh, Babol University of Medical Sciences, Iran

Title: Cancer/testis antigens: An expanding family of targets for cancer immunotherapy
George Kunudji, Bikbok Herbal Centre, Ghana

Title: Cancer immunology & diagnosis
Alex Agyekum, Bikbok Herbal Centre, Ghana

Panel Discussion

Networking & Refreshments @ Tullamarine

Lunch Break @ Vargas Restaurant

Closing Ceremony
Sponsorship

2nd International Conference on Tumor & Cancer Immunology and Immunotherapy
July 17-18, 2017   Chicago, Illinois, USA

Theme: Emerging Technologies and treatment in Tumor & Cancer immunotherapy from vaccines to antibodies and cell therapies

Why with us?

In today’s economic climate your business decisions are as crucial as ever. 2nd International Conference on Tumor & Cancer Immunology and Immunotherapy allows you to maximize your time and marketing dollars while receiving immediate feedback on your new products and services.

2nd International Conference on Tumor & Cancer Immunology and Immunotherapy is organizing an outstanding Scientific Exhibition/Program and anticipates the world’s leading specialists involved in .

Tumor & Cancer Immunology 2017 organizing committee anticipates over 300 participants to attend this premier event. Your organization will benefit with excellent exposure to the leaders in Immunology.

Tumor & Cancer Immunology 2017 is an exciting opportunity to showcase the new technology, the new products of your company, and/or the service your industry may offer to a broad international audience.

Lots of thoughts were put together planning to make this conference a premier event. Our worldwide Editorial Board Members of Journal of Immunotherapy, Journal of Immunooncology and Journal of Tumor Diagnostics and Reports have agreed to promote and support the event.

Exhibiting at 2nd International Conference on Tumor & Cancer Immunology and Immunotherapy will attain you with an exceptional format in showcasing your products and services. Conference Series Ltd Conferences and Exhibitions provide you one location to reach your top customers.

Premium Sponsorship Packages

Elite Sponsor

• An opportunity to sponsor 10 Poster Presentation Awards.
• Three corporate sponsored workshop slots (audio visual included).
• Two complimentary exhibit booths with priority to purchase exhibition space and choose booth location (Booth size-3X3 sqm).
• Four complimentary registrations.
• Logo recognition on congress website front page with link, logo recognition on congress sponsorship page and logo recognition on corresponding Conference Series Ltd Journal home page.
• One A4 color advertisement in the congress program or book of abstracts (excluding cover pages).
• Three inserts provided by the sponsor in the congress delegate bags.
• One post congress e-mail message to consented congress registrants up to 60 days after the congress (content to be provided by the sponsor, approved and distributed by corresponding Journal).
• An exclusive online Promotion on all our Social Networking Sites.
• 20% Waiver on Sponsorship for any of our next year conferences.

Gold Sponsor

• An opportunity to sponsor 5 Poster Presentation Awards.
• Two corporate sponsored workshop slot (must honor deadlines, catering and audio visual included).
• One complimentary exhibit booth with priority to purchase exhibition space and choose booth location (Booth size-3X3 sqm).
• Three complimentary congress registrations.
• Logo recognition on congress website front page with link and logo recognition on congress sponsorship page.
• One A4 color advertisement in the congress program or book of abstracts (excluding cover pages).
• Two inserts provided by the sponsor in the congress delegate bags.
• An exclusive online Promotion on all our Social Networking Sites.
• 15% Waiver on Sponsorship for any of our next year conferences.

**Silver Sponsor**

• An opportunity to sponsor 3 Poster Presentation Awards.
• Two complimentary congress registrations.
• One corporate sponsored workshop slot (must honor deadlines, catering and audio visual included).
• One complimentary exhibit booth with priority to purchase exhibition space and choose booth location (Booth size-3X3 sqm).
• Logo recognition on congress website sponsorship page.
• One A4 color advertisement in the congress program or book of abstracts (excluding cover pages).
• One insert provided by the sponsor in the congress delegate bags.
• Priority to purchase additional sponsorship items.
• An exclusive online Promotion on all our Social Networking Sites.
• 10% Waiver on Sponsorship for any of our next year conferences.

**Exhibition**

• An opportunity to sponsor one poster presentation award.
• One complimentary congress registration.
• Set up of one tailor-made exhibit booth (Booth Size 3x3 sqm).
• Logo recognition on congress website sponsorship page.
• A4 Color Advertisement in Congress Program or Book of Abstract.
• Inclusion of your company’s leaflet/insert in the congress delegate bags.
• An exclusive online promotion on all our social Networking Sites.
• 5% Waiver on Sponsorship for any of our next year conferences.
• Recognition to your products and services in the world market through our website.
• Develop new client relationships and strengthen the existing ones (B2B Meeting).
• Shape and raise your corporate image through logo branding.
• Brand briefing at
• Press Release on behalf of your company.
• Brand announcement with 50000 Brochures across the Globe.
• Sharing Conference Posters (10000) with Industries and Universities located across the globe.